Acticor Biotech: Disclosure of the Total Number of Voting Rights and Shares as of April 30, 2024
Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today